Chronic obstructive pulmonary disease has wrongly been thought to be progressive and non-responsive to therapy because of an inaccurate focus on airflow limitation as the sole outcome measurement, according to Celli (medicine, Tufts U. School of Medicine). After reviewing alternative measurement criteria (including hypertension, strokes, heart failure, and myocardial infarction), he explores the outcomes achieved by different pharmacological agents. Annotation ©2004 Book News, Inc., Portland, OR (booknews.com)
Placing specialists at the cutting-edge of therapeutic and biotechnological research, this reference reviews the extensive array of pharmaceutical options available for the management of patients with COPD. The book considers disease severity, dosing regimens, administration methods, and monitoring procedures, as well as medication-related side-effects for improved lung function, reduction of disease symptoms, and enhanced quality of life. Contributions from world-renowned authorities reflect recent practices, controversies, and procedures in the control of COPD symptoms and detail the development and efficacy of therapies such as anticholinergics, beta adrenergics, and corticosteroids.
